Updated 14:15 GMT, 21 Nov 2026 SPX 6,910.39 -3.70% NDX 25,028.98 -5.61% VIX 35.89 +26.20% GOLD 3,515.40 -4.62% CL 83.98 +0.93% BTC 60,166.89 +2.33%
NAS100 25,029 −5.61% S&P 6,910 −3.70% GOLD $3,515 −4.62% BTC $60,167 +2.33% VIX 35.89 +26.20% latest tape · as of 14:15 UTC
The Screen · Healthcare · Biotechnology

Corvus Pharmaceuticals, Inc. logoCorvus Pharmaceuticals, Inc.

CRVS · Nasdaq · USD · Market cap $888M · 37 employees

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of product candidates that precisely target proteins that are critical to immune cell maturation and function in the Un…

FAIL · Does not pass the screen
9.67 USD

Price as of 20 Nov 2026Daily close, not a live quote

Screened 2026-11-20 · the tape above runs as of 14:15 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed

Key facts today

  • Price9.67 USD at the 20 Nov 2026 close
  • Fair valueUnder review: our model's value is 2.81x the price, above our 2.00x limit.
  • Our regime readMarkup, as of 15 Nov 2026
  • Ethical screenDoes not pass
  • OptionsOpen interest leans heavily to calls (put/call 0.07)
  • Last reviewed20 Nov 2026 (1 day ago)
  • Release timesRelease and earnings times on your chart: Event Guard Mentor

A summary of the dated readings below, not a live quote and not advice.

PRICE · ONE YEAR

Our fair-value range: range not available (screen dated 2026-11-20).

Current read
Markup ?
Screened · screened 2026-11-20
  • Trend Markup
  • Insiders insiders bought, latest filing 2026-11-11
  • Positioning no disclosures inside 60 days, left as found
  • Options put/call open interest 0.07, read 2026-11-20
  • Ethical does not pass the values gate
Price9.67 USD
Fair valueUnder review
Ethical score70.0/100
Our investment reviews on this name
2026-11-12Read Markup11.47-15.7% to today Markdown gives way to Markup after an 8% slide in 6 weeks
2026-10-02Read Markdown12.42-22.1% to today ✓Accumulation gives way to Markdown after an 18% slide in 5 weeks
2026-08-26Read Accumulation15.14-36.1% to today Distribution gives way to Accumulation after a 27% rise in 8 weeks
2026-07-02Read Distribution11.93-18.9% to today ✓First review on file: Distribution

Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.

The full research record, in depth, below
The Label · The Season, Not the Day

This name holds its markup label.

Corvus Pharmaceuticals, Inc. holds its Markup at $9.67. The statistical read favours the sellers, held for 71 days.

As held on the ledger · 2026-11-20
PhaseMarkup
Quantitative stateThe statistical read favours the sellers, held for 71 days
Price at the screen$9.67
ValuationN/A trailing · -9.89 forward price to earnings
Values screenFAIL · score 70.0
Beta1.43
The Workings

Five Screens: CRVS's Results

FAIL. Interest-bearing securities

TestFigureLimitStatus
Business activity Permissible Permissible core business Pass
Debt load 1.32% Below 33% Pass
Interest-bearing cash 73.36% Below 33% Fail
Receivables 6.49% Below 49% Pass

Definitions, sources and threshold rules: ticker values-screen methodology.

The Ethical Read

Why It Falls Short, in Plain English

Corvus Pharmaceuticals,'s business is fine, but its cash and interest-bearing securities are about 73% of its assets, well over the ~33% line, so it does not pass on the financial screens.

Read as at 20 Nov 2026. It updates when the underlying figures move, and past reads are kept below. How we screen.

Follow this verdict

Get an email when CRVS's ethical verdict changes

Today CRVS does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.

Free, no account needed. Every email has a link to stop.

What the Numbers Say It Is Worth

The Fair Value Range

Fair value under review. Our model's value is 2.81x the price, above our 2.00x limit. We show no fair value, margin of safety or value read built on it until the review clears.

Method.

The Street's Range
27.00Street low 32.00Street average 42.00Street high 9.67Price

Street: 7 covering, consensus Strong Buy. Average target +231%.

Chart
The Business, in Plain Words

Clinical Biotech Hits Wall on Missing Data

Picture a lab racing to fine tune immune cells while the cash meter ticks down. Corvus is exactly that, a clinical stage group whose lead candidate targets proteins tied to immune function, yet it posts zero profit margins and a minus thirty per cent return on equity.

The numbers flag a double gap. Fair value sits at twice the current price and analysts eye thirty two dollars, yet the opportunity rating is none because the ethical screen returns insufficient data on basic ratios. Negative forward earnings and an unknown moat simply compound the absence of usable information.

Risk sits in the usual biotech traps of trial failure and dilution, made worse by the lack of any ethical baseline to judge governance or long term viability. Analysis, not advice.

The fundamentals · plain-English read
Forward P/E-9.9x
EPS, trailing-0.62
EPS, forward-1.07
Profit margin0.0%currently unprofitable
Return on equity-35.4%not currently earning a positive return on equity
FCF yield-3.08%
Debt to equity0.32minimal debt: a conservative balance sheet
Current ratio16.16comfortably covers its short-term bills
Beta1.43moves a little more than the market
Short interest, float0.23%
52-week range6.39 - 26.95
Market cap$888M
Employees37

CRVS-specific watchpoints · The things to watch: it's a small-cap, so the share price can swing harder than the market; it already moves more than the market on an average day; as a biotechnology name, trial and regulatory outcomes can move it sharply either way.

Metric definitions and interpretation rules: ticker-page methodology.

The Dated Journal · Newest First, Never Edited

Every Entry, As Written

2026-11-20 Markup $10.19 +0.0% Entry 21
2026-11-19 Markup $10.19 -11.2% Entry 20
2026-11-12 Markup · changed $11.47 +8.5% Entry 19

The framework has shifted from markdown to markup since the last review.

2026-11-05 Markdown $10.57 +7.5% Entry 18
2026-11-04 Markdown $9.83 -2.0% Entry 17
2026-11-03 Markdown $10.03 +0.0% Entry 16
2026-11-02 Markdown $10.03 +0.0% Entry 15
2026-11-01 Markdown $10.03 -2.0% Entry 14
2026-10-31 Markdown $10.23 +0.0% Entry 13
2026-10-30 Markdown $10.23 -2.8% Entry 12

Earnings landed in this window. Ethical screening: FAIL.

Written on its date, before the outcome; never pruned.

Latest News · What the Market Is Reading on CRVS

Headlines from third-party outlets, linked for reference: not our reporting, not advice.

Related Securities · Others in CRVS's Space

Screened names in the same industry · explore each on its own page.

The Insider Ledger · Form 4 Filings, As Filed
Most recent filings · CRVS
DateInsiderTitleTypeSharesValue
2026-11-11 Arcara Jeffrey Chief Business Officer P - Purchase 4,500 $50,475

Public filings, recorded as found. The full tape lives at Insider Intelligence.

What Holding Actually Paid · Price Plus Dividends
If $1,000 had been placed · historical, not a promise
PeriodPrice thenPrice returnDivs per share$1,000 becameTotal return
1 month $15.81 -29.0% · $710 -29.0%
2 months $15.10 -25.6% · $744 -25.6%
3 months $16.01 -29.9% · $701 -29.9%
6 months $8.40 +33.7% · $1,337 +33.7%
1 year $4.25 +164.2% · $2,642 +164.2%
2 years $2.10 +434.8% · $5,348 +434.8%
3 years $3.58 +213.7% · $3,137 +213.7%
5 years $2.80 +301.1% · $4,011 +301.1%

Historical returns from market close data. Past performance does not guarantee future results.

The Ledger's Promise

This entry now belongs to the ledger. Whatever CRVS does next, these words stay.

Corvus Pharmaceuticals, Inc. · CRVS · Markup · $9.67
Recorded 2026-11-20 · before the outcome · scored mechanically

Membership

Thirteen thousand names carry this page. One desk keeps them honest.

Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.

Join the desk

Screening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.

Get our weekly market brief free.